Evidence map›Paper›PMID 29468306›Full record

ArticleVirchows Archiv : an international journal of pathology2018

Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Tobias M Dantonello, Christian Vokuhl, Monika Scheer, Monika Sparber-Sauer, Sabine Stegmaier, Guido Seitz, Heike Scheithauer, Jörg Faber, Iris Veit-Friedrich, Peter Kaatsch and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Tobias M DantonelloPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany. t.dantonello@klinikum-stuttgart.de.ORCID http://orcid.org/0000-0003-0050-5327
Christian VokuhlKiel Pediatric Tumor Registry, Department of Pediatric Pathology, University of Kiel, Kiel, Germany.
Monika ScheerPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Monika Sparber-SauerPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Sabine StegmaierPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Guido SeitzDepartment for Pediatric Surgery, University of Marburg, Marburg, Germany.
Heike ScheithauerDepartment of Radiotherapy, Ludwig Maximilian University, Munich, Germany.
Jörg FaberDepartment of Pediatric Oncology, University of Mainz, Mainz, Germany.
Iris Veit-FriedrichPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Peter KaatschGerman Childhood Cancer Registry, Mainz, Germany.
Stefan S BielackPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Thomas KlingebielDepartment of Pediatric Oncology, University of Frankfurt (Main), Frankfurt, Germany.
Ewa KoscielniakPediatrics 5 (Oncology, Hematology, Immunology), Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Cooperative Weichteilsarkom Studiengruppe (CWS)
Olgahospital · DEChristian-Albrechts-Universität zu Kiel · DEGoethe University Frankfurt · DEJohannes Gutenberg University Mainz · DEPhilipps University of Marburg · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The alveolar subtype of rhabdomyosarcoma (RMA) is a strong risk factor. Cases of RMA located in paratesticular sites have however been reported to have similar outcomes to those of embryonal rhabdomyosarcoma (RME). We wanted to re-evaluate the impact of subtype in paratesticular rhabdomyosarcoma (PT-RMS). Patients from a population-based cohort diagnosed with paratesticular RMA in 1990-2013 were analyzed. All tumor samples were re-reviewed using conventional morphology, immunohistochemistry, and molecular testing. Seven patients were eligible. Four tumors showed focal areas morphologically compatible with RMA (mixed RMA/RME). One case was undifferentiated, with a solid round-cell morphology which had to be reclassified as poorly differentiated RME. Two cases had a "microalveolar" morphology which is today regarded as sclerosing RME. No tumor showed the characteristic gene fusion of RMA. Five children had localized disease, one bone metastases, and another lymph-node involvement. All primaries were grossly resected. One locoregional relapse occurred. At a median follow-up of 7 years, all patients were alive disease-free. PT-RMS can show a focal alveolar histology combined with typical features of RME. In current morphological classifications, all rhabdomyosarcomas qualify for the alveolar subtype if typical features of RMA are realized at least focally. Rhabdomyosarcomas consisting of pure RMA morphology were however not found in our patients with PT-RMS. The mixed RMA/RMEs identified in our population-based study did not show a translocation typical for RMA and had a good prognosis. Further prospective studies need to evaluate if mixed RMA/RMEs have a similar favorable outcome in non-paratesticular sites as well.

Indexed as

AdolescentChildChild, PreschoolHumansImmunohistochemistryLymphatic MetastasisMaleMesenchymomaPrognosisRhabdomyosarcomaSurvival AnalysisTesticular NeoplasmsAlveolar subtypeParatesticularPediatric oncologyRhabdomyosarcoma

Identifiers

PMID29468306
OpenAlexW2793101755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.